<DOC>
	<DOCNO>NCT01549392</DOCNO>
	<brief_summary>This study aim assess effect Avastin brain vascularity blood-brain permeability use dynamic contrast ct scan ( DECT ) MRI image . Previous publication document method DECT determine alteration vascular volume tissue permeability within tumor normal brain tissue . Functional map cerebral blood flow cerebral blood volume permeability-surface area generate DECT study assess tumor perfusion . MRI spectroscopy analyze brain chemistry detect tumour versus edema versus normal brain . Thirty patient receive MRI spectroscopy DECT imaging time presume recurrence 3 month later . 15 patient receive Avastin 15 patient receive Avastin standard treatment recurrence study DECT MRI spectroscopy baseline 3 month .</brief_summary>
	<brief_title>Imaging Study Glioblastomas Treated With Avastin</brief_title>
	<detailed_description>The clinical determination point tumour progression response difficult determine use standard diagnostic imaging ie CT/MRI especially follow previous treatment surgery , radiation chemotherapy . Hemorrhage , edema , inflammation vascular necrosis . Both MR spectroscopy DECT report able define area recurrent tumour oppose treatment-related effect . We wish investigate correlation MR spectroscopy DECT assess tumour progression response Avastin comparison patient receive Avastin . Health Canada approve Avastin clinical use patient recurrent glioblastoma previously receive temozolomide radiotherapy . We propose perform DECT scan baseline presume tumour progression 3 month determine effect tumour progression/response blood brain barrier permeability vascular volume . The group 15 patient compare group 15 patient receive Avastin recurrence involve DECT scan MR spectroscopy time radiological progression 3 month later .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Histological diagnosis glioblastoma clinical radiological evidence progression indicate RANO criterion 19 Previous radiation temozolomide chemotherapy Patients must receive Avastin chemotherapy secondline treatment Avastin group Studyspecific consent Failure meet inclusion criterion Pregnant lactate patient Allergy iodine CT contrast precludes DECT component study Claustrophobia preclude MR Spectroscopy component study Internal metal would preclude MRI scan</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>dynamic enhance ct scan</keyword>
	<keyword>mri spectroscopy</keyword>
	<keyword>recurrent glioma</keyword>
</DOC>